Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 Jul 26;6(14):4224-4227.
doi: 10.1182/bloodadvances.2022007854.

A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia

Alessandro Broccoli  1   2 , Lisa Argnani  2 , Matthew Cross  3 , Agnieszka Janus  4 , Elsa Maitre  5 , Xavier Troussard  5 , Tadeusz Robak  4 , Claire Dearden  3 , Monica Else  6 , Daniel Catovsky  6 , Pier Luigi Zinzani  1   2
Affiliations
Multicenter Study

A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia

Alessandro Broccoli et al. Blood Adv. .

Abstract

  1. Cladribine is regarded as the first treatment of choice for symptomatic hairy cell leukemia.

  2. This large international study reports a complete response in 72% of cases and a continuous complete response in 20% of patients.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
DFS, PFS, and OS curves for the whole study population.
See this image and copyright information in PMC

References

    1. Troussard X, Maître E, Cornet E. Hairy cell leukemia 2022: update on diagnosis, risk-stratification, and treatment. Am J Hematol. 2022;97(2):226-236. - PubMed
    1. Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol. 2003;21(5):891-896. - PubMed
    1. Andrasiak I, Rybka J, Wrobel T. Response to therapy in hairy cell leukemia: systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2018;18(6):392-399.e3. - PubMed
    1. Noel P. Definition of remission, minimal residual disease, and relapse in hairy cell leukemia bone marrow biopsy histology and immunohistology specimens. Leuk Lymphoma. 2011;52(sup2 Suppl 2):62-64. - PubMed
    1. Broccoli A, Terragna C, Nanni L, et al. . Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia. Hematol Oncol. 2022;40(1):57-62. - PMC - PubMed

Publication types

MeSH terms